"Phase I trial of alpha-particle immunotherapy with 225Ac-lintuzumab and low-dose cytarabine in patients age 60 or older with untreated acute myeloid leukemia." The Journal of Nuclear Medicine Vol. 58 (2017) p. 456 - 456
Available at: http://works.bepress.com/john-pagel/10/